SCHEDULE 13G/A: BlackRock Discloses 9.4% Passive Stake in Arcus Biosciences
Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 9.4% passive beneficial ownership stake in Arcus Biosciences Inc. as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 9,977,061 shares of Arcus Biosciences Inc. common stock.
- This ownership represents 9.4% of the total outstanding common shares of Arcus Biosciences Inc.
- BlackRock holds sole voting power over 9,912,885 shares and sole dispositive power over 9,977,061 shares.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- This filing is an Amendment No. 5 to a previously filed Schedule 13G, indicating an update to an existing ownership disclosure.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing (Schedule 13G) disclosing passive ownership. It contains no operational or financial performance data for the issuer, nor does it suggest any strategic intent beyond passive investment. Therefore, the sentiment is neutral as it provides factual ownership information without positive or negative implications for the company's performance or outlook.
Industry Context
This filing represents a routine disclosure by a major institutional investor, BlackRock, regarding its passive stake in a biotechnology company, Arcus Biosciences. Such disclosures are common in the financial industry as large asset managers regularly adjust their portfolio holdings and are required to report significant ownership thresholds. It does not indicate a strategic shift for Arcus Biosciences but rather reflects BlackRock's investment decisions within the biotech sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's passive stake, confirming BlackRock's continued investment in the company.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of the previously revoked Power of Attorney. |
| 2025-01-21 | Effective date of the new Power of Attorney, revoking the prior one. |
| 2025-03-31 | Date of the event which requires the filing of this statement. |
| 2025-04-17 | Date of filing of this Schedule 13G Amendment No. 5. |
Keywords
BlackRock, Arcus Biosciences, Schedule 13G, Passive Investment, Institutional Ownership, Common Stock, SEC Filing, Beneficial Ownership, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.